** Shares of ARCA Biopharma jump ~87% to $3.2 premarket
** Company to merge with private biotech Oruka Therapeutics in all-stock deal
** Oruka has secured $275 mln stock and warrant funding to support the deal from a group of healthcare investors led by Fairmount and Venrock Healthcare Capital Partners
** Newly formed combined company will operate as Oruka Therapeutics and trade on Nasdaq under the ticker symbol "ORKA"
** Cash balance at deal closing is expected to fund Oruka's operations through 2027
** Cash balance to support development of Oruka's experimental drug candidates, ORKA-001 and ORKA-002, as potential treatments for chronic skin diseases
** ABIO shareholders will own about 2.4% of the combined company, while Oruka stockholders and investors will own the rest
** As of last close, ABIO up ~1% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.